1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline profile

1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, also known as **6,7-dimethoxy-1-phenylisoquinoline**, is a synthetic compound with a complex chemical structure. It is related to the natural alkaloid **tetrahydroisoquinoline** and bears structural similarities to several known pharmaceuticals.

Here's why it's important for research:

**1. Potential Therapeutic Applications:**

* **Antidepressant Activity:** Studies suggest 6,7-dimethoxy-1-phenylisoquinoline may have antidepressant properties. It has been shown to inhibit the reuptake of dopamine and norepinephrine, neurotransmitters involved in mood regulation, potentially mimicking the action of existing antidepressant medications.
* **Anxiolytic Activity:** Research indicates it may also exhibit anxiolytic (anxiety-reducing) effects. This is partly attributed to its interaction with the serotonin system, another neurotransmitter crucial for mood and anxiety management.
* **Antipsychotic Activity:** Some studies suggest its potential as an antipsychotic agent. Its interaction with dopamine receptors, known to be implicated in psychosis, is a focus of ongoing research.

**2. Chemical and Pharmacological Research:**

* **Structural Analogs:** The compound serves as a basis for developing new drug candidates. Its chemical structure can be modified to create analogs with improved potency, selectivity, and pharmacokinetic properties.
* **Pharmacokinetic Studies:** Research investigates its absorption, distribution, metabolism, and excretion (ADME) profile. Understanding these properties is vital for developing safe and effective drugs.
* **Mechanism of Action:** Studies aim to elucidate the precise mechanisms by which 6,7-dimethoxy-1-phenylisoquinoline exerts its biological effects. This knowledge is crucial for refining its potential therapeutic use and developing new drugs with similar mechanisms.

**3. Chemical Synthesis and Drug Discovery:**

* **Synthesis Methods:** Research focuses on developing efficient and scalable methods for synthesizing 6,7-dimethoxy-1-phenylisoquinoline. This is essential for obtaining sufficient quantities for research and potential clinical trials.
* **Structure-Activity Relationships:** Researchers study the relationship between the compound's chemical structure and its biological activity. By modifying the molecule, they can explore how changes impact its efficacy and side effects.

**4. Animal Models and Preclinical Studies:**

* **Animal Models:** 6,7-dimethoxy-1-phenylisoquinoline is investigated in animal models of depression, anxiety, and other neurological disorders. These studies help evaluate its therapeutic potential and identify potential safety concerns.
* **Preclinical Trials:** Preclinical studies assess the compound's safety and efficacy before moving to human trials.

**It's important to note that 6,7-dimethoxy-1-phenylisoquinoline is still in the early stages of research.** While it holds promise, further studies are necessary to validate its therapeutic potential, optimize its properties, and determine its safety and effectiveness in humans.

1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	151186
CHEMBL ID	258275
SCHEMBL ID	7849270
MeSH ID	M0098531

Synonym
EU-0073707
BB 0262591
6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-isoquinoline
OPREA1_431638
CBDIVE_002469
IDI1_011416
isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-phenyl-
1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
MAYBRIDGE3_000029 ,
OPREA1_167132
MLS001181471
smr000567162
CHEMBL258275
AKOS000117809
HMS1431B07
6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline
F0911-3475
NCGC00246624-01
4118-36-9
STK520582
EN300-09172
CCG-108084
HMS2865H21
AKOS016037542
mfcd00218177
SCHEMBL7849270
6,7-dimethoxyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline
1,2,3,4-tetrahydro-1-phenyl-6,7-dimethoxyisoquinoline
6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline #
6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline, aldrichcpr
sr-01000452893
SR-01000452893-1
Z55993050
1-(phenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
AS-37810
DTXSID60961486
A873122
1-phenyl-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline
1,2,3,4-tetrahydro-6,7-dimethoxy-1-phenylisoquinoline

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	0.6310	0.0447	17.8581	100.0000	AID485294
Smad3	Homo sapiens (human)	Potency	0.3981	0.0052	7.8098	29.0929	AID588855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID351812	Anticonvulsant activity in ip dosed DBA/2 mouse assessed as inhibition of auditory stimulation-induced tonic seizures administered 30 mins before auditory stimulation	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides.
AID326389	Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agents in vitro.
AID326390	Cytotoxicity against human C8166 cells after 72 hrs by MTT method	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agents in vitro.
AID326391	Selectivity index, ratio of CC50 for C8166 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agents in vitro.
AID351813	Anticonvulsant activity in ip dosed DBA/2 mouse assessed as inhibition of auditory stimulation-induced clonic seizures administered 30 mins before auditory stimulation	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (7.14)	18.7374
1990's	2 (14.29)	18.2507
2000's	3 (21.43)	29.6817
2010's	6 (42.86)	24.3611
2020's	2 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	1.95	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.07	1	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.04	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.05	1	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker

Condition	Relationship Strength	Studies
HIV Coinfection [description not available]	2.04	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.04	1
Absence Seizure [description not available]	2.05	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.95	1

1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline

Description

Cross-References

Synonyms (39)

Protein Targets (2)

Potency Measurements

Bioassays (21)

Research

Studies (14)

Market Indicators

Research Demand Index: 12.12

Study Types

1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline

Description

Cross-References

Synonyms (39)

Protein Targets (2)

Potency Measurements

Bioassays (21)

Research

Studies (14)

Market Indicators

Research Demand Index: 12.12

Study Types

Related Drugs (4)

Related Conditions (11)